Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza Clinical Trial

Official title:

A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02612922
• Other study ID #: RM08-3003
• Status: Completed
• Phase: Phase 3
• First received: November 20, 2015
• Last updated: April 2, 2018
• Start date: December 2015
• Est. completion date: September 4, 2016

Study information

• Verified date: April 2018
• Source: Romark Laboratories L.C.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.

Description:

A multicenter randomized double-blind placebo controlled trial designed to evaluate efficacy and safety of NTZ 600 mg administered orally twice daily for five days compared to a placebo in the treatment of acute uncomplicated influenza.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 325
• Est. completion date: September 4, 2016
• Est. primary completion date: September 4, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 12 to 65 years

2. Presence of clinical signs and/or symptoms consistent with an acute illness compatible with influenza infection (each of the following is required):

• oral temperature of =100.4°F or =38°C (obtained in office or self-measured within 12 hours prior to screening - if self-measured, subject must also have taken an antipyretic within 4 hours prior to screening) AND

• at least one of the following respiratory symptoms (cough, sore throat, nasal obstruction), AND

• one of the following constitutional symptoms (fatigue, headache, myalgia, feverishness).

3. Confirmation of influenza A or B infection in the local community by one of the following means:

• the institution's local laboratory,

• the local public health system,

• the national public health system, or

• a laboratory of a recognized national or multinational influenza surveillance scheme.

4. Onset of illness no more than 40 hours before enrollment in the trial.

Note: Time of onset of illness is defined as either the earlier of:

• the time when the temperature was first measured as elevated, OR

• the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.

5. Willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the patient diary.

Exclusion Criteria:

1. Severity of illness requiring or anticipated to require in-hospital care or subject defined as being at high risk of complications from influenza infection according to the Infectious Diseases Society of America (IDSA) guidelines for seasonal influenza in adults and children (Committee of Infectious Diseases (CID) 2009:48) or current Centers for Disease Control and Prevention (CDC) criteria. Current criteria for persons 12-65 years of age who are at risk of influenza complications include (list to be reviewed and updated as required prior to initiation of the study and at least monthly during the study):

• Persons with asthma or other chronic pulmonary diseases, such as cystic fibrosis in children or chronic obstructive pulmonary disease in adults.

• Persons with hemodynamically significant cardiac disease.

• Persons who have immunosuppressive disorders or who are receiving immunosuppressive therapy.

• Human Immunodeficiency Virus (HIV) infected persons.

• Persons with sickle cell anemia or other hemoglobinopathies.

• Persons with diseases requiring long-term aspirin therapy, such as rheumatoid arthritis or Kawasaki disease.

• Persons with chronic renal dysfunction.

• Persons with liver disorders.

• Persons with active cancer.

• Persons with chronic metabolic disease, such as diabetes mellitus, inherited metabolic disorders and mitochondrial disorders.

• Persons with neuromuscular disorders, seizure disorders or cognitive dysfunction that may compromise the handling of respiratory secretions.

• Residents of any age of nursing homes or other long-term care institutions.

• Persons who are morbidly obese (Body Mass Index =40).

• American Indians.

• Alaskan natives.

2. Females of childbearing potential who are either pregnant, breast-feeding or are sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post-treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, an intrauterine device (IUD), or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral ovariectomy.

3. Vaccination for seasonal influenza on or after August 1, 2015.

4. Receipt of any dose of nitazoxanide, oseltamivir, zanamivir, peramivir, amantadine or rimantadine within 30 days prior to screening.

5. Prior treatment with any investigational drug therapy within 30 days prior to screening.

6. Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies.

7. Known sensitivity to nitazoxanide or any of the excipients comprising the nitazoxanide tablets.

8. Subjects unable to take oral medications.

9. Subject has chronic kidney or liver disease (including Hepatitis A, B or C) or known impaired hepatic and/or renal function.

10. Presence of any other pre-existing chronic infection that is undergoing or requiring medical therapy.

11. Presence of any pre-existing illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study.

12. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for five days
• Placebo
Placebo administered orally twice daily for five days

Locations

Country	Name	City	State
Australia	Influence Study Site	Berwick	Victoria
Australia	Influence Study Site	Brookvale	New South Wales
Australia	Influence Study Site	Browns Plains	Queensland
Australia	Influence Study Site	Castle Hill	New South Wales
Australia	Influence Study Site	Lynbrook	Victoria
Australia	Influence Study Site	Mosman	New South Wales
Australia	Influence Study Site	Rosebud	Victoria
Australia	Influence Study Site	Springfield	Queensland
Australia	Influence Study Site	Tarneit	Victoria
Puerto Rico	Influence Study Site	San Juan
Puerto Rico	Influence Study Site	San Juan
United States	Influence Study Site	Anaheim	California
United States	Influence Study Site	Austin	Texas
United States	Influence Study Site	Columbus	Georgia
United States	Influence Study Site	Fresno	California
United States	Influence Study Site	Hot Springs	Arkansas
United States	Influence Study Site	Houston	Texas
United States	Influence Study Site	Jackson	Tennessee
United States	Influence Study Site	Kissimmee	Florida
United States	Influence Study Site	Lansdale	Pennsylvania
United States	Influence Study Site	Lauderdale Lakes	Florida
United States	Influence Study Site	Lomita	California
United States	Influence Study Site	Pharr	Texas
United States	Influence Study Site	Plano	Texas
United States	Influence Study Site	Rapid City	South Dakota
United States	Influence Study Site	Saint Cloud	Florida
United States	Influence Study Site	Savannah	Georgia
United States	Influence Study Site	Waco	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Romark Laboratories L.C.

Countries where clinical trial is conducted

United States,  Australia,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to alleviation of all clinical symptoms of influenza		Up to 28 days
Secondary	Time to alleviation of each individual symptom of influenza		Up to 28 days